Current Pain and Headache Reports

, Volume 6, Issue 2, pp 151–155 | Cite as

Should butalbital-containing analgesics be banned? Yes.

  • William B. Young
  • Hua Chiang Siow


In the United States analgesic-overuse headache is often caused by butalbital-containing analgesics. These agents can cause physical and psychological dependency, and dangerous withdrawal syndromes. Butalbital-containing analgesics have already been banned in several European countries. They are proven effective in tension-type headache, but not in migraine; there are many alternative treatments for migraine and tension-type headache. In the 20 years since analgesic overuse headache was widely recognized, butalbital overuse has remained distressingly common. It is time to ban these agents.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Castillo J, Munoz P, Guitera V, Pascual J: Epidemiology of chronic daily headache in the general population. Headache 1999, 39:190–196.PubMedCrossRefGoogle Scholar
  2. 2.
    Scher AI, Stewart WF, Liberman J, Lipton RB: Prevalence of frequent headache in a population sample. Headache 1998, 38:497–506.PubMedCrossRefGoogle Scholar
  3. 3.
    Newman LC, Lipton RB, Stewart WF: Severe daily headache in a population sample: results from the American migraine study (submitted for publication). 1998 (UnPub).Google Scholar
  4. 4.
    Diamond S, Dalessio DJ: Drug abuse in headache. In The Practicing Physician’s Approach to Headache. Edited by Diamond S, Dalessio DJ. Baltimore: Williams & Wilkins; 1982:114–121Google Scholar
  5. 5.
    Wilkinson M: Introduction. In Drug Induced Headache. Edited by Diener HC, Wilkinson MS. Berlin: Springer-Verlag; 1988:1–2.Google Scholar
  6. 6.
    Mathew NT: Drug induced headache. Neurol Clin 1990, 8:903–912.PubMedGoogle Scholar
  7. 7.
    Saper JR: Ergotamine: dependency: a review. Headache 1987, 27:435–438.PubMedCrossRefGoogle Scholar
  8. 8.
    Saper JR: Chronic headache syndromes. Neurol Clin 1989, 7:387–412.PubMedGoogle Scholar
  9. 9.
    Silberstein SD, Lipton RB, Solomon S, Mathew NT: Classification of daily and near daily headaches: proposed revisions to the IHS classification. Headache 1994, 34:1–7.CrossRefGoogle Scholar
  10. 10.
    Saper JR, Jones JM: Ergotamine tartrate dependency: features and possible mechanisms. Clin Neuropharmacol 1986, 9:244–256.PubMedCrossRefGoogle Scholar
  11. 11.
    Andersson PG: Ergotism: the clinical picture. In Drug Induced Headache. Edited by Diener HC, Wilkinson MS. Berlin: Springer-Verlag; 1988:16–19Google Scholar
  12. 12.
    Rapoport AM, Weeks RE, Sheftell FD, et al.: The “analgesic washout period”: a critical variable evaluation in the evaluation of headache treatment efficacy. Neurology 1986, 36:100–101.Google Scholar
  13. 13.
    Baumgartner C, Wessly P, Bingol C, et al.: Long-term prognosis of analgesic withdrawal in patients with drug-induced headaches. Headache 1989, 29:510–514.PubMedCrossRefGoogle Scholar
  14. 14.
    Mathew NT, Reuveni U, Perez F: Transformed or evolutive migraine. Headache 1987, 27:102–106.PubMedCrossRefGoogle Scholar
  15. 15.
    Warner JS: Rebound headaches: a review. Headache 1999, 10:207–219.Google Scholar
  16. 16.
    Kudrow L: Paradoxical effects of frequent analgesic use. Adv Neurol 1982, 33:335–341.PubMedGoogle Scholar
  17. 17.
    Rapoport AM: Analgesic rebound headache. Headache 1988, 28:662–665.PubMedCrossRefGoogle Scholar
  18. 18.
    Diener HC, Dichgans J, Scholz E, et al.: Analgesic-induced chronic headache: long-term results of withdrawal therapy. J Neurol 1989, 236:9–14.PubMedCrossRefGoogle Scholar
  19. 19.
    Rasmussen BK, Jensen R, Olesen J: Impact of headache on sickness absence and utilization of medical services. J Epidemiol Community Health 1992, 46:443–446.PubMedCrossRefGoogle Scholar
  20. 20.
    Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgia, and facial pain. Cephalalgia 1988, 8:1–96.CrossRefGoogle Scholar
  21. 21.
    Silberstein SD, Lipton RB, Sliwinski M. Classification of daily and near-daily headaches: field trial of revised IHS criteria. Neurology 1996, 47:871–875.PubMedGoogle Scholar
  22. 22.
    Silverman K, Evans SM, Strain EC, Griffiths RR: Withdrawal syndrome after the double-blind cessation of caffeine consumption. N Engl J Med 1992, 327:1109–1114.PubMedCrossRefGoogle Scholar
  23. 23.
    Scholz E, Diener HC, Geiselhart S, Wilkinson M: Drug-induced headache: does a critical dosage exist? In Drug-Induced Headache. Edited by Diener HC. Berlin: Springer-Verlag; 1988:29–43.Google Scholar
  24. 24.
    Fisher CM: Analgesic rebound headache refuted. Headache 1988, 28:666.PubMedCrossRefGoogle Scholar
  25. 25.
    Bowdler I, Killian J, Gänsslen-Blumberg S: The association between analgesic abuse and headache: coincidental or causal. Headache 1990, 30:494.Google Scholar
  26. 26.
    Lance F, Parkes C, Wilkinson M: Does analgesic abuse cause headache de novo? Headache 1988: 61–62.Google Scholar
  27. 27.
    Silberstein SD, McCrory DC. Butalbital in the treatment of headache: history, pharmacology, and efficacy. Headache 2001, 41:953–967. A comprehensive evaluation of butalbital compounds in the management of headache disorders and the danger associated with butalbital use.PubMedCrossRefGoogle Scholar
  28. 28.
    Friedman AP: Assessment of Fiorinal with codeine in the treatment of tension headache. Clin Ther 1986, 8:703–721.PubMedGoogle Scholar
  29. 29.
    Friedman AP, Boyles WF, Elkind AH, et al.: Fiorinal with codeine in the treatment of tension headache: the contribution of components to the combination drug. Clin Ther 1988, 10:303–315.PubMedGoogle Scholar
  30. 30.
    Friedman AP, Diserio FJ: Symptomatic treatment of chronically recurring tension headache: a placebocontrolled, multicenter investigation of Fioricet and acetaminophen with codeine. Clin Ther 1987, 10:69–81.PubMedGoogle Scholar
  31. 31.
    Glassman JM, Soyka JP: Muscle contraction (tension) headache: a double blind study comparing the efficacy and safety of meprobamate-aspirin with butalbital-aspirinphenacetin-caffeine. Curr Ther Res 1980, 28:904–909.Google Scholar
  32. 32.
    Goldstein J, Gawel MJ, Winner P, et al.: Comparison of butorphanol nasal spray and fiorinal with codeine in the treatment of migraine. Headache 1988, 38:516–522.CrossRefGoogle Scholar
  33. 33.
    Hwang DS, Mietlowski MJ, Friedman AP: Fiorinal with codeine in the management of tension headache: impact of placebo response. Clin Ther 1987, 9:201–222.PubMedGoogle Scholar
  34. 34.
    Thorpe P: Controlled and uncontrolled studies on “Fiorinal-PA” for symptomatic relief in tension headache. Med J Aust 1970, 2:180–181.PubMedGoogle Scholar
  35. 35.
    von Graffenried B, Hill RC, Nuesch E: Headache as a model for assessing mild analgesic drugs. J Clin Pharmacol 1980, 20:131–144.Google Scholar
  36. 36.
    vonGraffenried B, Nuesch E: Nonmigrainous headache for the evaluation of oral analgesics. J Clin Pharmacol 1980, 10:225–231.Google Scholar
  37. 37.
    Sellers EM, Hoornweg K, Busto UE, Romach MK: Risk of drug dependence and abuse posed by barbiturate-containing analgesics. Can J Clin Pharmacol 1999, 6:18–25. A review of the safety of barbiturates alone and in combination with analgesics.PubMedGoogle Scholar
  38. 38.
    McLean W, Boucher EA, Brennan M, et al.: Is there an indication for the use of barbiturate-containing analgesic agents in the treatment of pain? Guidelines for their safe use and withdrawal management. Can J Clin Pharmacol 2000, 7:191–197. A summary on the effectiveness, safety, and risks associated with barbiturate-containing analgesics and on the approach to management of withdrawal for barbiturate-containing analgesics.PubMedGoogle Scholar
  39. 39.
    Hobbs WR, Rall TW, Verdoorn TA: Hypnotics and sedatives: ethanol. In The Pharmacological Basis of Therapeutics. Edited by Goodman LS, Gilman A. New York: McGraw-Hill; 1996:361–396.Google Scholar
  40. 40.
    Micromedex®: Butalbital. Martindale: The Complete Drug Reference. (Volume 107). 2000. Micromedex® Healthcare Series.Google Scholar
  41. 41.
    Kay DC, Blackburn AB, Buckingham JA, Karacan I: Human pharmacology of sleep. In Pharmacology of Sleep. Edited by Williams RL, Karacan L. New York: John Wiley & Sons; 1976:83–210.Google Scholar
  42. 42.
    Mendelson WB, Gillin JC, Wyatt RJ: Human Sleep and Its Disorders. New York: Plenum Press; 1977.Google Scholar
  43. 43.
    Ciraulo DA, Greenblatt DJ: Sedative-, hypnotic-, or anxiolyticrelated disorders. In Comprehensive Textbook of Psychiatry. Edited by Kaplan HI, Sadock BJ. Baltimore: Williams & Wilkins; 1995:872–887.Google Scholar
  44. 44.
    Sullivan JT, Sellers EM: Treatment of the barbiturate abstinence syndrome. Med J Aust 1986, 145:456–458.PubMedGoogle Scholar
  45. 45.
    Fraser HF, Wikier A, Essig CF, Isbell H: Degree of physical dependence induced by secobarbital or pentobarbital. JAMA 1958, 166:126–129.Google Scholar
  46. 46.
    Hering R, Steiner TJ: Abrupt outpatient withdrawal from medication in analgesic-abusing migraineurs. Lancet 1991, 337:1442–1443. An observational study supporting the role of analgesic overuse as a factor in chronic daily headache.PubMedCrossRefGoogle Scholar
  47. 47.
    Raja M, Altavista MC, Azzoni A, Albanese A: Severe barbiturate withdrawal syndrome in migrainous patients. Headache 1996, 36:119–121.PubMedCrossRefGoogle Scholar
  48. 48.
    Lipton RB, Stewart WF, VonKorff M: Burden of migraine: societal costs and therapeutic opportunities. Neurology 1997, 48:4–9.Google Scholar
  49. 49.
    Lipton RB, Stewart WF, VonKorff M: The burden of migraine: a review of cost to society. Pharmaco Economics 1994, 6:215–222. Direct and indirect costs for migraine society.Google Scholar
  50. 50.
    Meletiche DM, Lofland JH, Young WB: Quality of life differences between patients with episodic and transformed migraine. Headache 2001, 41:573–578.PubMedCrossRefGoogle Scholar
  51. 51.
    Diener HC, Gerber WD, Geiselhart S: Short and long-term effects of withdrawal therapy in drug-induced headache. In Drug-Induced Headache. Edited by Diener HC, Wilkinson M. Berlin: Springer-Verlag; 1988:133–142.Google Scholar
  52. 52.
    Osterhaus JT, Gutterman DL, Plachetka JR: Healthcare resource and lost labor costs of migraine headache in the United States. Pharmaco Economics 1992, 2:67–76.Google Scholar
  53. 53.
    VonKorff M, Stewart WF, Simon DS, Lipton RB: Migraine and reduced work performance: a population-based diary study. Neurology 1998, 50:1741–1745.Google Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • William B. Young
    • 1
  • Hua Chiang Siow
    • 1
  1. 1.Jefferson Headache CenterDepartment of Neurology, Thomas Jefferson UniversityPhiladelphiaUSA

Personalised recommendations